Observational studies suggest that proton pump inhibitors (PPIs) are a risk factor for incident Clostridium diffi cile infection (CDI). Data also suggest an association between PPIs and recurrent CDI, although large-scale studies focusing solely on hospitalized patients are lacking. We therefore performed a retrospective cohort analysis of inpatients with incident CDI to assess receipt of PPIs as a risk factor for CDI recurrence in this population.
INTRODUCTION
Proton pump inhibitors (PPIs) are a risk factor for incident Clostridium difficile infection (CDI) ( 1 -3 ) . PPIs are among the most common drugs in the world; in the America, esomeprazole was the third most prescribed drug by sales in 2011 ( 4 ) . They are highly effective in treating gastric acid-related disorders ( 1 ) but are often prescribed without a documented indication ( 5, 6 ) . Other established risk factors for CDI include older age, antibiotics, hospitalization, and gastrointestinal tract abnormalities ( 7, 8 ) ; PPIs appear to act synergistically with other risk factors to increase the risk of incident C. difficile among both inpatients and outpatients ( 9, 10 ) .
Up to 30 % of patients with CDI recur aft er completing treatment ( 11 ) and limited data suggests that PPIs may be a risk factor for recurrent as well as incident CDI. A study combining inpatients and outpatients at eight Veterans Aff airs medical centers in New England suggested that PPIs were associated with a moderately increased risk of recurrent CDI ( 12 ) . Two smaller studies reached similar conclusions although with heterogeneity in their estimates of risk ( 13, 14 ) .
Th e factors that infl uence C. diffi cile recurrence diff ers between inpatients and outpatients. Inpatients with incident CDI are older, have more comorbidities, and are more oft en exposed to antibiotics compared with outpatients ( 15 ) . Inpatients with CDI are more likely to have been exposed to PPIs compared with outpatients; when PPIs are given, there are diff erences between inpatients and outpatients in indications for use, duration, dosage, and method of administration ( 16 ) . Furthermore, inpatients have more severe C. diffi cile and are more likely to be exposed to hypervirulent subtypes such as the North American Pulsed Field type 1 strain ( 17, 18 ) .
For these reasons, factors that infl uence Clostridium diffi cile recurrence may have distinct strengths of association in the inpatient setting as opposed to the outpatient setting. Yet studies to date have not focused on PPIs as a risk factor for recurrence exclusively among inpatients with CDI. We therefore sought to study the relationship between in-hospital use of PPIs and recurrent CDI in a retrospective cohort analysis of inpatients with CDI.
METHODS

Study population
We electronically reviewed the medical records from all adult inpatients at our institution testing positive for C. diffi cile from 1 September 2009 to 30 June 2012. (1 September 2009 was the day on which our institution switched from a C. diffi cile immunoassay to the stool PCR test for C. diffi cile toxin B.) From this group, we identifi ed all patients with incident CDI, defi ned as a positive stool PCR test while hospitalized from 1 December 2009 to 30 June 2012 without a prior positive test within 90 days who were treated for C. diffi cile . To minimize loss to follow-up, we excluded from the analysis patients who did not meet study end points or did not have proven clinical follow-up in our medical system as evidenced by a clinical encounter aft er the 90-day study period ( Figure 1 ). Th e Institutional Review Board of Columbia University Medical Center approved this study.
Measures
Using automated electronic queries, we extracted information regarding age, sex, self-reported race / ethnicity, length of stay, and hospitalization in an intensive care unit during the index admission. Death was extracted from the electronic medical record, which is cross-indexed with the National Social Security Death Index. We additionally extracted information regarding medications received during the C. diffi cile treatment period including PPIs, acid suppression with a histamine-2 receptor antagonist (H2RA), type of C. diffi cile treatment, non-CDI antibiotics, and immunosuppressants. Discharge summaries were manually reviewed to extract information regarding discharge PPIs or other acid suppression, non-CDI antibiotics, and immunosuppressants. However, because discharge summaries were frequently missing or incomplete ( n = 181), we ultimately did not include these variables in the analyses. Patients receiving solely H2RAs for gastric acid suppression were classifi ed as having received H2RAs; those receiving H2RAs concurrent with PPIs were classifi ed as having received PPIs. Type of C. diffi cile treatment was categorized as metronidazole alone, vancomycin alone, or both medications; none of the patients in the study received fi daxomicin. Steroids were considered to be immunosuppressive only if prescribed at a dose of at least 5 mg prednisone daily or equivalent.
Our electronic medical record uses standard International Classifi cation of Diseases (ICDs) coding to describe patient comorbidities. We found that ICD coding of patient comorbidities was inaccurate compared with manual review, a phenomenon that has been previously described ( 19, 20 ) . To avoid the limitations of ICD codes, we used a natural language processing system called Medical Language Extraction and Encoding (MedLEE) to electronically process admission notes and extract patient comorbidities ( 21 ) . MedLEE is a rule-based program that transforms natural language clinical text into computable data ( 22 -24 ) ; here MedLEE captured comorbidity variables with 88 % accuracy compared with a subset manual chart review ( 25 ) . Comorbidities were described in a modifi ed Charlson comorbidity index ( 26 ) omitting tumors with / without metastases and mild liver disease because these distinctions could not be clearly made from existing records.
Primary exposure and outcome
Th e primary exposure was defi ned a priori as in-hospital PPI therapy at any dose and at least daily in frequency for a minimum of 2 days during the C. diffi cile treatment period. Th e primary outcome was defi ned as a second positive PCR for the C. diffi cile ( 27, 28 ) . To select the recurrence window of 15 -90 days, we referred to studies suggesting that (i) most patients respond to C. diffi cile treatment within 3 -4 days and over 90 % are cured aft er 14 days of standard treatment ( 29, 30 ) and (ii) CDI recurrence risk peaks 7 -30 days aft er cessation of antibiotics but persists for up to 90 days ( 31, 32 ) . Patients were censored at death or 90 days aft er their initial positive test. In order to determine the duration of exposure to PPIs, we manually reviewed patients ' electronic medical records to identify the clinical encounters preceding the date of recurrence (among those who had recurrent CDI) or the date of censoring (among those who did not have recurrent CDI). We then recategorized PPI duration as follows: none, partial duration (PPIs given either concurrent with C. diffi cile treatment or during the follow-up period but not during both times), and full duration (PPIs given concurrent with C. diffi cile treatment and during follow-up). In order to determine the relationship between strength of acid suppression and recurrent CDI, we defi ned four categories of acid suppression given during C. diffi cile treatment: no PPIs, solely H2RAs, low-dose PPIs (equivalent to esomeprazole 20 mg daily or less), and high-dose PPIs (equivalent to more than esomeprazole 20 mg daily).
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Statistical analysis
Categorical variables were analyzed using chi-squared tests (for data satisfying the central limit theorem) or Fisher ' s exact tests and continuous variables were analyzed using t -tests (for normally distributed data) or Wilcoxon rank sum tests. C. diffi cile recurrence rates in the PPI exposed and unexposed groups were compared with the log-rank test. Multivariable Cox proportional hazards modeling was performed to assess the association between PPIs and CDI recurrence, controlling for potential confounders. We included the following variables in the model: age, sex, race / ethnicity, comorbidities (modifi ed Charlson score), type of C. diffi cile treatment, receipt of antibiotics, receipt of immunosuppressants, intensive care unit stay, and hospital length of stay. In post hoc analyses, we examined the subset of patients who survived to complete 90 days of follow-up and assessed for associations between PPI duration and recurrent CDI and between PPI dose and recurrent CDI. All data were analyzed using SAS 9.3 (SAS Institute, Cary, NC, USA) at the alpha 0.05 level of signifi cance.
RESULTS
Patient characteristics
We identified 894 hospitalized patients with a newly positive stool PCR test for C. difficile toxin B between 1 December 2009 and 30 June 2012 and documented follow-up in our medical system. Overall, 62 % of patients received PPIs concurrently with CDI treatment. Only 32 patients (4 % ) received acid suppression with H2RAs alone. Over 98 % of patients receiving PPIs were given esomeprazole. Patient received similar rates of PPIs whether they were among those analyzed or among the 323 patients who did not have follow-up in our medical system ( P = 0.50). Among those with recurrent CDI, 93 of 167 (56 % ) were receiving a PPI at the time of the diagnosis of CDI recurrence; among those who did not have recurrent CDI, 406 of 727 (56 % ) were receiving a PPI at the time of censoring. Among the 167 patients with recurrent CDI, 33 patients (20 % ) recurred during the index admission with a median time to recurrence of 33 days (range 15 -67 days). An additional 66 patients (40 % ) were discharged but recurred during a subsequent admission, whereas 68 patients (41 % ) recurred as outpatients.
Baseline and hospitalization-related risk factors
At the time of hospital admission, patient demographic and clinical characteristics were similar between those who did and did not receive PPIs concurrent with CDI treatment ( Table 1 ). However, during hospitalization patients who received PPIs were more likely to receive antibiotics and immunosuppressants compared with patients who did not receive PPIs and were more likely to be treated for C. diffi cile with both metronidazole and vancomycin, a potential indication of severe disease. In addition, patients who were given PPIs during C. diffi cile treatment had signifi cantly longer hospitalizations, were more likely to be hospitalized in an intensive care unit, and more likely to die within 90 days compared with patients who were not given PPIs ( Table 2 ).
Multivariable analysis
Th e primary outcome of recurrent CDI occurred in 167 patients with a cumulative incidence of 22 % among those who received PPIs concurrent with C. diffi cile treatment compared with 24 % among those who did not receive PPIs (log-rank P = 0.56; Figure 2 ). In multivariable analysis, the adjusted hazard ratio (HR) for PPIs was 0.82 (95 % confi dence interval (CI) = 0.58 -1.16; Table 3 ). When acid suppression with H2RAs was added to the model to assess for a dose-related eff ect (subjects categorized as no acid suppression, H2RAs only, or PPIs), there was no change in the relationship between PPIs and CDI recurrence and no association between receipt of H2RAs and CDI recurrence. Black race was identifi ed as an independent predictor of CDI recurrence (HR = 1.66, 95 % CI = 1.05 -2.63). Older age and increased comorbidities at the time of admission were also signifi cantly associated with CDI recurrence.
Sensitivity analysis
Th e cumulative 90-day mortality within the population was signifi cantly higher among patients who received PPIs compared with those who did not (log-rank P = 0.02), although PPIs were not associated with mortality in a multivariable analysis (HR = 0.95, 95 % CI = 0.71 -1.27). To assess the possibility of death as a competing risk, we examined the patients who survived through 90 days of follow-up aft er the initial positive test. Among this subset of 635 patients there was no association between PPIs and CDI recurrence (HR = 0.87, 95 % CI = 0.60 -1.28). Because Multiple observational studies have suggested that PPIs are a risk factor for incident CDI yet doubt remains as to whether PPIs are truly causal in C. diffi cile or whether the observed relationship is due to unmeasured confounding ( 33, 34 ) . By focusing exclusively on inpatients with CDI, the current study minimizes clinical heterogeneity between patients who did and did not receive PPIs. In addition to PPIs, other risk factors for incident CDI include older age, antibiotics, hospitalization, and gastrointestinal tract abnormalities ( 8 ) . Previously identifi ed 
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DISCUSSION
Among 894 hospitalized patients with C. diffi cile at our institution, we found no association between receipt of PPIs during C. diffi cile treatment and CDI recurrence within 15 -90 days aft er the initial positive test. Th is result remained null in a post hoc subset analysis of patients who survived to complete 90 days of follow-up and in analyses based on duration and dose of PPI exposure. Interestingly, black race was identifi ed as an independent predictor of recurrence. Increased age and increased comorbidities were also associated with CDI recurrence. 
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PPIs and Recurrent C. difficile risk factors for recurrent CDI include older age and antibiotics as well as use of acid-suppressing medicines ( 35 -37 ) . Our data support older age as an independent risk factor for recurrent CDI. Th ree prior studies have found that PPIs were associated with a moderately increased likelihood of CDI recurrence ( 12 -14 ) . Ascertainment of comorbidities, defi nitions of PPI exposure, and the populations under consideration all diff er between our study and prior studies. Although methodological diff erences make it challenging to compare populations, our patients appear to have had more severe CDI as evidenced by the large portion (41 % ) who were treated with both metronidazole and vancomycin compared with under 10 % in the other studies. It is possible that the pathogenesis of CDI recurrence varies between patients with severe CDI and relatively healthier patients with C. diffi cile . Th is is the fi rst study to fi nd that black race may be an independent risk factor for recurrent CDI. Previous studies have suggested that black race may be protective of incident CDI ( 38 -40 ) , whereas prior studies of recurrent CDI have not assessed race ( 12 -14 ) . Th e observed association between black race and CDI recurrence in the present study may be mediated by factors that infl uence the microbiome such as diet, biological diff erences such as a diff erence in mean serum albumin level ( 41 ), or socioeconomic factors such as insurance status, access to medicines, or nursing home residency status. Future studies are warranted to identify the specifi c factors responsible for the observed association between black race and C. diffi cile recurrence.
Although our study does not support an association between PPIs and recurrent C. diffi cile , there is robust observational data supporting an association between PPIs and incident C. diffi cile . Th e mechanism by which PPIs might cause incident CDI is uncertain ( 1 ). C. diffi cile spores are acid resistant and acid suppression has little impact on their survival ( 42, 43 ) . However, gastric acid suppression with PPIs may alter the colonic microbiome to decrease colonization resistance or other normal barriers to C. diffi cile proliferation. Th e microbiome is vital in maintaining normal immunity ( 44 ) and in animals, PPIs alter the colonic microbiome in a manner similar to antibiotics ( 45 -47 ) . It is biologically plausible that PPIs might contribute to incident CDI by perturbing the micro biome yet have little eff ect on CDI recurrence because the microbiome of patients at risk for recurrence is already altered.
Th is study has multiple strengths. Th is is the fi rst large study to focus exclusively on inpatients with CDI who receive PPIs. CDI is oft en a nosocomial disease and the factors driving inpatient vs. outpatient CDI are diff erent; this study directly addresses the question of whether inpatients with CDI can be given PPIs during C. diffi cile treatment without increasing risk for CDI recurrence. Because all patients were hospitalized, we were able to ascertain primary exposure and outcome with high confi dence. We extracted comorbidities from the medical record using natural language processing, which is more accurate than ICD coding ( 22 -24 ) . We also evaluated a time period during which C. diffi cile diagnosis was based on stool PCR testing, which has improved test parameters compared with earliergeneration immunoassays ( 28 ) . Our study is relatively large, incorporates time to recurrence in the primary analysis, and adequately assesses other possible explanations for recurrence of CDI, including patient risk factors, antibiotics, and other acid suppression.
Th ere are some limitations to our study. Diarrhea is a common side eff ect of PPIs and could lead to increased testing for C. diffi cile . However, increased testing among patients who received PPIs would have biased fi ndings away from the null, toward a positive association between PPIs and recurrent CDI. Although our study was relatively large, it was not powered to detect very small diff erences in CDI recurrence rates among patients exposed to PPIs compared with patients who were not exposed. Our patients had a high degree of comorbidity and our results may not be generalizable to healthier inpatient populations. Despite exclusion of patients who lacked adequate clinical follow-up, we do not have a closed hospital system and patients may have had recurrence diagnosed elsewhere. However, our methods were designed to minimize such losses, there was no evidence of diff erential loss to follow-up by receipt of PPIs, and our overall recurrence rate was similar to prior studies ( 12, 48 ) . Patients in our study who received PPIs received almost exclusively esomeprazole. However, there is no evidence that type of PPI modifi es the relationship between PPIs and CDI; we believe that our fi ndings regarding esomeprazole and recurrent CDI are indicative of a class eff ect.
In sum, among hospitalized patients with newly diagnosed Clostridium diffi cile , administration of PPIs concurrently with C. diffi cile treatment was not a risk factor for CDI recurrence. Black race, increased age, and additional comorbidities were predictive of recurrence. Our primary results are best applied to populations that resemble the patients in our study -patients in tertiary care settings with a high degree of illness and multiple comorbidities. Although hospitalized patients frequently receive PPIs without indication, in-hospital administration of PPIs does not increase the risk of CDI recurrence. Future studies should test interventions to prevent CDI recurrence among high-risk inpatients.
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